Schizophrenia Research

Schizophrenia is a chronic, debilitating mental disorder affecting 1-2% of the global population. Symptoms are split into two types; 'positive' symptoms, including delusions and hallucinations, and 'negative' symptoms, including anhedonia and lack of motivation. Studies suggest that genetics, early environment, neurobiology, psychological and social processes are important contributory factors; some recreational and prescription drugs appear to cause or worsen symptoms. Several neurobiological alterations in brain structure, physiology and neurochemistry have been documented, along with an ever-increasing list of susceptibility genes.

Schizophrenia Research Products Targets

Products for Schizophrenia Research - Page 2

  1. Cat.No. Product Name Information/Activity
  2. BCC6804 (±)-threo-3-Methylglutamic acid 63088-04-0 (±)-threo-3-Methylglutamic acid chemical structure
  3. BCC6873 MPDC MPDC is a potent and competitive inhibitor of the Na+-dependent high-affinity glutamate transporter in forebrain synaptosomes. MPDC chemical structure
  4. BCC6595 L-trans-2,4-PDC 64769-66-0 L-trans-2,4-PDC chemical structure
  5. BCC6840 SYM 2081 SYM 2081 is a high-affinity ligand and potent, selective agonist of kainate receptors, inhibits [3H]-kainate binding with an IC50 of 35 nM, almost 3000- and 200-fold selectivity for kainate receptors over AMPA and NMDA receptors respectively. SYM 2081 chemical structure
  6. BCC5735 DL-TBOA DL-TBOA is a potent non-transportable inhibitor of excitatory amino acid transporters with IC50s of 70 μM, 6 μM and 6 μM for excitatory amino acid transporter-1 (EAAT1), EAAT2 and EAAT3, respectively. DL-TBOA inhibits the uptake of [14C]glutamate in COS-1 cells expressing the human EAAT1 and EAAT2 with Ki valuesof 42 μM and 5.7 μM, respectively. DL-TBOA blocks EAAT4 and EAAT5 in a competitive manner with Ki values of 4.4 μM and 3.2 μM, respectively. DL-TBOA chemical structure
  7. BCC5919 TFB-TBOA 480439-73-4 TFB-TBOA chemical structure
  8. BCC7692 UCPH 101 UCPH-101 is an excitatory amino acid transporter subtype 1 (EAAT1) inhibitor with an IC50 of 0.66 μM. UCPH 101 chemical structure
  9. BCC7442 WAY 213613 WAY-213613 is a potent, selective nonsubstrate reuptake inhibitor of GLT-1/EAAT2 with IC50 of 85 nM EAAT2. It displays 59- and 44-fold selectivity over EAAT1 and EAAT3 (IC50s are 5 and 3.8 μM, respectively). WAY-213613 shows no activity at ionotropic and metabotropic glutamate receptors. It is a potential tool for the elucidation of EAAT2 function. WAY 213613 chemical structure
  10. BCC5896 MNI-caged-D-aspartate 845555-94-4 MNI-caged-D-aspartate chemical structure
  11. BCC4530 Histamine 2HCl Histamine dihydrochloride is an endogenous metabolite. Histamine 2HCl chemical structure

Items 11 to 20 of 709 total